Trevi Therapeutics, which is developing a drug to treat chronic itching in patients with the skin condition prurigo nodularis, has completed enrollment in its latest drug trial.
President and CEO Jennifer Good called it an “important milestone” in the development of its drug Haduvio.
The drug is taken orally and provides an extended-release formulation of nalbuphine, which is currently approved in the U.S. and Europe and marketed as an injectable for pain.